8-K: Anixa Breast Cancer Vaccine Phase 1 Data Positive

Anixa Biosciences announced positive final Phase 1 clinical trial data for its investigational breast cancer vaccine, meeting primary endpoints and showing immune response.

Summary

• Anixa Biosciences and The Cleveland Clinic Foundation presented final data from the Phase 1 clinical trial of their investigational breast cancer vaccine (NCT04674306) at the 2025 San Antonio Breast Cancer Symposium (SABCS).
• The trial, funded by a grant from the U.S. Department of Defense, evaluated safety and immune response to a vaccine targeting -lactalbumin (aLA).
• The investigational vaccine met all major primary endpoints, was safe and well tolerated at the maximum tolerated dose (MTD), and elicited protocol-defined immune responses in 74% of participants.
• Adverse events were primarily injection-site irritation, with no flu-like symptoms or abnormal clinical laboratory tests reported in Cohort Ia.
• The study enrolled 35 participants across three cohorts: women with early-stage TNBC at risk of recurrence (n=26), cancer-free women with BRCA1/2/PALB2 mutations electing preventive mastectomy (n=4), and women with TNBC receiving pembrolizumab (Keytruda) in the adjuvant setting (n=5).
• In Cohort Ic, the combination of Keytruda and the vaccine generated antigen-specific T cell responses and showed no major additional side effects, though two participants experienced Grade 3 injection-site irritation.
• The positive results support the advancement of the program into Phase 2 development, including a potential combination study with Keytruda in the neoadjuvant setting for newly diagnosed breast cancer patients.

Sentiment

Score: 9

Explanation: The filing reports highly positive final Phase 1 clinical trial data, meeting all primary endpoints, demonstrating safety, and eliciting strong immune responses. This significantly de-risks the program and supports advancement to Phase 2, which is a major positive milestone for a biotechnology company.

Positives

• All major primary endpoints of the Phase 1 clinical trial for the investigational breast cancer vaccine were met.
• The vaccine was safe and well tolerated at the Maximum Tolerated Dose (MTD), with adverse events primarily limited to injection-site irritation.
• A significant majority, 74% of participants, demonstrated protocol-defined immune responses, including -lactalbumin (aLA)-specific T cell responses.
• The combination of the vaccine with pembrolizumab (Keytruda) generated antigen-specific T cell responses and showed no major additional side effects, supporting future combination studies.
• The positive data supports the advancement of the program into Phase 2 development, including a planned combination study with Keytruda in newly diagnosed breast cancer patients.
• The study was supported by a grant from the U.S. Department of Defense.

Negatives

• Two participants in Cohort Ic, who received the vaccine in combination with pembrolizumab, experienced Grade 3 adverse events consisting of greater irritation at an injection site.

Risks

• Statements that are not historical fact may be considered forward-looking statements, which involve risks, uncertainties, and other factors, some beyond our control, that may cause actual results, performance, or achievements to be materially different from those expressed or implied.
• These risks, uncertainties, and factors include, but are not limited to, those set forth in Item 1A Risk Factors and other sections of our most recent Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Future Outlook

The positive final Phase 1 data supports the advancement of the breast cancer vaccine program into Phase 2 development. Plans include a potential Phase 2 combination study with Keytruda in the neoadjuvant setting among newly diagnosed breast cancer patients. Participants from the Phase 1 study will be followed for five years after completing the study to monitor long-term outcomes.

Management Comments

• "In this trial, the investigational -lactalbumin vaccine was safe and well tolerated at the maximum tolerated dose and generated protocol-defined immune responses in 74% of participants—results that support continued clinical evaluation." G. Thomas Budd, M.D., Cleveland Clinic's Cancer Institute and principal investigator.
• "Our findings that the majority of participants across all three cohorts demonstrated an immune response to -lactalbumin is an encouraging sign." Justin Johnson, Ph.D., Program Manager at Cleveland Clinic and co-inventor.
• "We are very encouraged that the final Phase 1 data met all major primary endpoints, with the vaccine demonstrating a favorable tolerability profile at the MTD and protocol-defined immune responses in the majority of participants." Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
• "We appreciate the support provided through the U.S. Department of Defense grant that enabled this study in collaboration with Cleveland Clinic, and we look forward to engaging with regulators and advancing plans for a Phase 2 study." Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.

Industry Context

This announcement represents a significant step forward in the development of a novel approach to combat breast cancer, particularly triple-negative breast cancer (TNBC), which remains one of the most challenging subtypes to address. The focus on immunization against retired proteins aligns with innovative trends in oncology, seeking to harness the immune system for both treatment and prevention. The collaboration with a renowned institution like Cleveland Clinic and funding from the U.S. Department of Defense underscore the potential impact of this research within the broader biotechnology and cancer treatment landscape.

Related Party Transactions

• The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa Biosciences.
• Cleveland Clinic is entitled to royalties and other commercialization revenues from Anixa Biosciences related to these vaccine technologies.

Stakeholder Impact

• Shareholders: Positive news likely to increase investor confidence and potentially share price due to successful clinical trial progression.
• Patients: Offers hope for a new treatment and preventative option for breast cancer, particularly triple-negative breast cancer.
• Employees: Positive development for the company's pipeline, potentially boosting morale and job security.
• Cleveland Clinic: Strengthens its reputation as a research institution and provides potential future royalty income.
• U.S. Department of Defense: Successful outcome for a grant-funded project, validating their investment in medical research.

Next Steps

• Advance the breast cancer vaccine program into Phase 2 development.
• Plan a potential Phase 2 combination study with Keytruda in the neoadjuvant setting for newly diagnosed breast cancer patients.
• Engage with regulators regarding future development plans.
• Present ongoing immunohistochemistry analyses of resected breast tissue in a future scientific presentation.
• Follow participants for five years after completing the study.

Key Dates

Recommendation

The successful completion of Phase 1 with all primary endpoints met, strong immune response, and good safety profile significantly de-risks the investigational breast cancer vaccine. The clear path to Phase 2, including a combination study with an established drug like Keytruda, indicates strong potential for future value creation. For a biotechnology company, positive Phase 1 data is a critical milestone that warrants a 'buy' recommendation for investors seeking growth in the oncology space, despite the inherent risks of clinical development.

Keywords

breast cancer vaccine, Anixa Biosciences, Cleveland Clinic, Phase 1 clinical trial, triple-negative breast cancer, immunotherapy, cancer prevention, alpha-lactalbumin, Keytruda, oncology, biotechnology, clinical development